radar could shift
treatment paradigm orphan diseas
deep dive preview expect around upcom first data
poc trial recal develop orphan
diseas congenit adren hyperplasia retain low profil
date estim market us could support robust
uptak current get credit drug therefor earli signal
efficaci could see rise w/ minim downsid
commerci opp potenti boost top-line growth recent investor focu
ingrezza quarterli rev expect launch elagolix partner buy
howev see pot respect top-line contribut review
mechan address market pt us w/ classic form
target think adult ped pt could benefit addit
drug soc steroid replac sinc steroid-spar effect expect even w/
price lower end orphan drug spectrum calcul potenti us peak
sale opp
studi provid poc data first-in-class mechan
inhibitor differenti directli block releas upstream hormon acth
drive androgen product importantli steroid minim lower acth
level neg feedback requir high dose suppress androgen top-line
result would look mod-robust reduct key biomark baselin
posit signal activ acth easili monitor androgen precursor
androstenedion downstream androgen think reduct acth
reduct androstenedion could support move program
replac address lack endogen product howev accumul steroid
intermedi convert androgen control excess androgen remain
unmet need furthermor chronic steroid exposur carri risk lower
modified-releas hydrocortison formul increment improv upon exist
steroid regimen late-stag competitor pivot trial though could potenti
pt dcf-base risk includ clinic regulatori commerci
pleas see analyst certif import disclosur inform inform regard statu non-u analyst page report
conduct deep-div market opportun surround congenit adren
hyperplasia preview expect neurocrin bioscienc nbi-
inhibitor ahead upcom top-line result proof-of-concept
trial expect
expect follow data proof concept support move
program later stage clinic studi
regard acth biomark would expect reduct vs baselin
earli morn window
would expect reduct vs baselin earli morn
hour think improv could also drive similar
decreas baselin androstenedion level
estim preval patient think vast
major diagnos treat think could repres
market opportun therefor posit proof concept data could lead
share increas dont see much downsid risk given
program consensus/jef model
expect nbix proof-of-concept
trial
studi like incorpor design element pib studi
termin drug conduct open-label poc studi
young adult male femal age year old classic
split evenli among two dose cohort enrol patient assess baselin
hormon profil period prior start treatment window
follow-up period unspecifi length biomark assess acth
hydroxyprogesteron androgen cortisol manag otherwis
disclos specif around protocol trial list clinicaltri gov
order anticip aspect studi design turn publish result pib
trial differ investig inhibitor
discontinu due toxic seen long-term safeti studi juvenil
pib studi conduct use single-blind placebo-control two
dose design enrol adult femal age year old classic inclus
criteria specifi serum cutoff level morn ng/dl acth pg/ml
cortisol mcg/dl exhibit subject receiv stabl steroid replac
regimen begin day prior enrol continu
durat studi subject receiv fix sequenc single-dos treatment
follow order placebo mg mg
treatment separ washout interv prevent confound effect
steroid replac therapi withheld hour start
day treatment follow day subject serv control
hormon profil placebo compar profil
page
pleas see import disclosur inform page report
mg biomark reportedli assess acth androstenedion
testosteron cortisol
exhibit inclus criteria pib studi vs normal refer rang
result studi show inhibit suppress mean acth
ohp level morn window hormon
expect rise placebo dose result mean acth pg/ml mean
ng/dl valu mean sd result dose
mix reduct mean acth mean vs
placebo respect howev dose post mean acth
pg/ml mean ng/dl repres reduct
mean acth mean vs placebo respect exhibit note studi
wasnt power stat biomark outcom androgen cortisol
werent report publish paper investig also classifi patient
respond level declin least one timepoint
patient met criterion respond characterist
includ younger age year old normal weight/borderlin overweight
think like leverag learn trial design
studi foremost clear single-blind two dose design patient
serv control adopt modif rather
sequenti receiv placebo studi drug separ washout period appear
placebo omit favor baselin hormon profil taken
immedi prior dose also appear subject separ
two cohort receiv one two dose subject
expect continu background steroid replac therapi though like
dose withheld and/or day treatment cleanli visual
effect also expect dose occur prior bedtim counter acth
surg occur upon awaken remain unclear number dose
administ length follow-up given pib studi evalu singl
extend timepoint hour post-treat would expect studi cover
window addit one long-term follow-up assess
page
pleas see import disclosur inform page report
adult maleadult mcg/dl repres earli morn valu premenopaus femal lower menstrual follicular phase higher menstrual luteal phasebiomarkernorm refer rang pib inclus criteria ng/dl
exhibit mean respons plasma acth morn window singl dose nbi-
exhibit individu respons plasma acth morn window singl dose
proof-of-concept focu acth androstenedion given
trial poc studi dont think power stat howev
discuss import biochem outcom would view
constitut posit signal activ greenlight pursuit random placebo-
reduct acth vs baselin level one key readout acth
level given purport mechan directli inhibit secret
hormon replac steroid act indirectli reduc androgen
page
pleas see import disclosur inform page report
mean sd pg/ml reduct placebomean sd ng/ml reduct chang placebomean classifi respond least reduct placebo level one timepoint within chang dose mg
level exert neg feedback hypothalamus-pituitary-adren
hpa axi directli regul either crf acth secret contrast
inhibit receptor pituitari gland directli prevent
crf peptid stimul acth releas sinc mechan act
upstream steroid possibl drug achiev better suppress
hpa axi lower dose compar steroid note supra-physiolog level
steroid need activ neg feedback mechan sinc
dysregul feedback loop patient less respons chronic
exposur steroid trial saw mean reduct acth
critic earli morn window dose
previou night think similar decreas acth level
window would help valid mechan bode well
continu develop nice-to-hav would durabl effect beyond
hour singl dose assess studi could
potenti monitor follow-up period studi
reduct vs baselin level princip substrat
hydroxylas diagnosi base detect accumul
ohp also easili monitor sinc level patient often
upper limit normal uln therefor one would clearli expect
declin primari readout efficaci therapi
trial saw mean reduct level critic
window dose previou night reason
expect well acth suppress durabl
effect beyond hour singl dose would consid plu also
possibl investig decid benchmark reduct hard
cutoff respond vs non-respond declin level
one timepoint done
studi case would look least half patient show
respons accord select cutoff
reduct androstenedion vs baselin level defect hydroxylas
enzym result shunt accumul substrat
androgen synthesi pathway first convert androstenedion
androgen intermedi subsequ end product testosteron
dihydrotestosteron therefor reduct androstenedion would
indic downstream efficaci therapi provid mean address
viril one key unmet need interestingli
studi androstenedion mention biomark investig
result werent report final public sinc accumul
ohp eventu convert androgen would ballpark expect mean
reduct assumpt decreas
translat commensur decreas androstenedion
mechan
target pituitari receptor repres first-in-class
mechan cure would requir correct mutated/delet
gene encod feasibl approach would use non-steroid
agent block synthesi and/or releas adrenocorticotrop hormon acth sinc
elev acth primari driver dysregul adren androgen product
select oral avail non-peptid corticotropin-releas factor
receptor antagonist competit inhibit receptor locat
corticotrop cell pituitari gland crf secret hypothalamu bind
receptor pituitari cell stimul releas acth blockad
page
pleas see import disclosur inform page report
receptor reduc acth releas preclin model valid approach first-
in-human studi theori upstream inhibit acth could effect reduc adren
androgen product also elimin need high-dos steroid also
hypothes directli inhibit acth effect mechan reli
neg feedback steroid note amount steroid replac
alway requir patient treat drug
target sinc impair enzym still unabl produc
normal quantiti corticosteroid
diurnal chronocort offer glimps success set-up
registr studi chronocort extended-releas synthet cortisol
replac develop diurnal substitut convent steroid regimen
presum advantag chronocort better drug-releas profil
close mimic peak trough endogen cortisol secret
circadian period could translat better hormon metabol control
open-label studi chronocort adult classic male-to-femal
conduct nih subject dose mg
twice daili month dose individu titer within first
two week treatment patient serv control baselin hormon
profil measur convent steroid therapi compar result collect
month treatment chronocort
publish result chronocort demonstr statist signific decreas
ohp level compar baselin month treatment median nmol/l vs
nmol/l valu period fall within normal
rang oppos valu baselin detail pk analysi
month chronocort statist signific decreas achiev area
curv auc hour morn
compar baselin similarli androstenedion auc decreas significantli
hour morn
afternoon/even compar baselin notabl decreas
acth numer lower reach statist signific mallappa et al clin
term clinic outcom statist signific chang bodi mass
index whole bodi bone miner densiti bmd qualiti life/fatigu
month though signific increas lean bodi mass note
averag steroid dose hydrocortison dose equival slightli less chronocort
mg/dose compar convent therapi mg/dose
summari chronocort show superior control androgen compar
convent steroid clinic outcom improv period
mallappa et al clin endocrinol metab howev overal find
suffici posit diurnal move forward piii registr trial
chronocort us eu
eu piii pivot trial open-label studi recent complet enrol
patient across clinic site random continu treatment
standard-of-car steroid chronocort bid month primari endpoint control
androgen month equival lower dose chronocort
determin chang level compar baselin similar trial
secondari endpoint includ clinic outcom bodi mass index bone turnov
page
pleas see import disclosur inform page report
fatigu level top-line data eu trial expect file
could potenti submit us piii pivot trial slate begin
enrol patient random chronocort bid immediate-releas
hydrocortison tid primari endpoint biochem control assess
ohp secondari endpoint compar eu trial patient
complet either us eu pivot trial allow continu cross
onto chronocort extens studi clinic outcom appear regul
want see long-term clinic benefit though biochem control could suffici
secur initi label potenti set preced later competitor
millendo report posit top-line data nevanimib poc
millendo compound nevanimib formerli develop classic
mechan inhibit adren enzym convert
cholesterol cholesterol ester earliest precursor molecul requir
product corticosteroid androgen
success reduc adren steroid steroid intermedi poc studi
enrol adult patient baselin uln primari endpoint
reduc uln recal nbix pib studi set cutoff
ng/dl baselin roughli equat uln given
ng/dl repres uln therefor approxim millendo cutoff follow
placebo lead-in period patient dose lowest dose nevanimib
week reduc uln patient underw washout
period escal next highest dose total dose level could
triall mg patient reach primari endpoint
undergo dose escal
millendo result report endocrin societi annual meet
march difficult compar data head-on nbix previou trial
patient millendo studi titrat toward goal uln
wherea nbix studi focus mean percent reduct baselin
without target level unclear mean percentag reduct
achiev nevanimib though patient achiev pre-specifi
primari endpoint uln note one patient discontinu due seriou
ae enter exclud analysi treat stress-dos
steroid millendo also classifi patient fail meet primari endpoint
potenti respond show mean reduct treatment
period howev appli stringent criterion mean reduct
ohp respond trial also possibl compar individu
patient across trial sinc millendo report maxim mean chang
ohp per patient basi
spruce pursu nbix-lik trial design though
mechan remain undisclos privat biotech spruce singl pipelin
compound current develop classic discoveri phase
undisclos indic though public inform spars note poc
studi contain similar design element nbix trial
total adult patient enrol two dose cohort baselin
hour hormon profil drawn prior treatment period first cohort
patient dose undisclos amount dose daili week
page
pleas see import disclosur inform page report
